MX2015012541A - Anticuerpos anti-tgf-beta modificados geneticamente y fragmentos de union a antigeno. - Google Patents

Anticuerpos anti-tgf-beta modificados geneticamente y fragmentos de union a antigeno.

Info

Publication number
MX2015012541A
MX2015012541A MX2015012541A MX2015012541A MX2015012541A MX 2015012541 A MX2015012541 A MX 2015012541A MX 2015012541 A MX2015012541 A MX 2015012541A MX 2015012541 A MX2015012541 A MX 2015012541A MX 2015012541 A MX2015012541 A MX 2015012541A
Authority
MX
Mexico
Prior art keywords
antigen
human
binding fragments
antibodies
tgf
Prior art date
Application number
MX2015012541A
Other languages
English (en)
Other versions
MX365385B (es
Inventor
Ronnie Wei
Huawei Qiu
Clark Pan
Aaron Moulin
Magali Mathieu
Sunghae Park
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2015012541A publication Critical patent/MX2015012541A/es
Publication of MX365385B publication Critical patent/MX365385B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se diseñan anticuerpos o fragmentos de unión a antígeno de los mismos para que se unan al Factor de Crecimiento Transformante ß (TGFß). Los anticuerpos o fragmentos de unión a antígeno de los mismos selectivos de las isoformas de TGF-ß se pueden unir selectivamente a TGFß1 humano, en comparación con TGFß2 humano y TGFß3 humano, o se pueden unir selectivamente a TGFß3 humano, en comparación con TGFß1 humano y TGFß2 humano. El diseño de los anticuerpos o fragmentos de unión a antígeno de los mismos se facilita por una estructura co-cristalina de un fragmento Fab recombinante de GC1008 unido a TGFß2 y por otra estructura co-cristalina de la versión scFv de GC1008 unido a TGFß1.
MX2015012541A 2013-03-11 2014-03-11 Anticuerpos anti-tgf-beta modificados genéticamente y fragmentos de unión a antígeno. MX365385B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776430P 2013-03-11 2013-03-11
PCT/US2014/023274 WO2014164709A2 (en) 2013-03-11 2014-03-11 Engineered anti-tgf-beta antibodies and antigen-binding fragments

Publications (2)

Publication Number Publication Date
MX2015012541A true MX2015012541A (es) 2016-02-10
MX365385B MX365385B (es) 2019-05-31

Family

ID=51659302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012541A MX365385B (es) 2013-03-11 2014-03-11 Anticuerpos anti-tgf-beta modificados genéticamente y fragmentos de unión a antígeno.

Country Status (27)

Country Link
US (2) US9783604B2 (es)
EP (2) EP2971048B1 (es)
JP (1) JP6495884B2 (es)
KR (1) KR102258457B1 (es)
CN (1) CN105229160B (es)
AR (1) AR095240A1 (es)
AU (2) AU2014249051B2 (es)
BR (1) BR112015021595A2 (es)
CA (1) CA2904847C (es)
CY (1) CY1121412T1 (es)
DK (1) DK2971048T3 (es)
ES (2) ES2845215T3 (es)
HK (1) HK1220731A1 (es)
HR (1) HRP20190201T1 (es)
HU (1) HUE042020T2 (es)
IL (1) IL241404B (es)
LT (1) LT2971048T (es)
MX (1) MX365385B (es)
PL (1) PL2971048T3 (es)
PT (1) PT2971048T (es)
RU (1) RU2681502C2 (es)
SG (2) SG10201707021RA (es)
SI (1) SI2971048T1 (es)
TR (1) TR201901415T4 (es)
TW (2) TWI613216B (es)
UY (1) UY35384A (es)
WO (1) WO2014164709A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3705498A1 (en) 2013-08-22 2020-09-09 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
EP3234120A4 (en) 2014-12-15 2018-05-16 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
US9884900B2 (en) 2015-08-04 2018-02-06 Acceleron Pharma Inc. Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
KR20180092947A (ko) * 2015-10-30 2018-08-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 형질 전환 성장 인자-베타-반응성 폴리펩티드 및 이의 사용 방법
PL3368579T3 (pl) * 2015-10-30 2022-03-21 F. Hoffmann-La Roche Ag Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania
AU2017268234A1 (en) 2016-05-17 2018-12-13 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
JP2019533003A (ja) * 2016-08-11 2019-11-14 プレシセラ，インコーポレイテッド ＴＧＦ−βアンタゴニストコンジュゲート
CA3039136A1 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
DK3628049T3 (da) 2017-05-04 2023-08-14 Acceleron Pharma Inc Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
EP3707510B1 (en) 2017-11-06 2024-06-26 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
JP2021531254A (ja) * 2018-07-11 2021-11-18 スカラー ロック インコーポレイテッドScholar Rock, Inc. 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2022157773A2 (en) * 2021-01-21 2022-07-28 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
CN112851819B (zh) * 2021-01-25 2023-08-11 华中科技大学同济医学院附属同济医院 结合小鼠PD-L1和TGF-β的双特异性抗体及其制备方法与应用
CA3208365A1 (en) 2021-02-15 2022-08-18 Chantal KUHN Cell therapy compositions and methods for modulating tgf-b signaling
CN113480645B (zh) * 2021-07-16 2022-11-11 甘肃中科博瑞生物工程有限公司 一种抗幽门螺旋杆菌重组抗体、制备方法及用途
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
RU2157406C2 (ru) * 1993-08-10 2000-10-10 Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU8525098A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2358400C (en) 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
DK1263464T3 (da) 2000-03-09 2013-01-28 Genzyme Corp Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion
US20030180301A1 (en) 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
EP2012814B1 (en) 2006-04-12 2013-05-22 Genzyme Corporation Methods of treating autoimmune diseases
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
ES2702049T3 (es) 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
EP2835053B1 (en) 2010-03-12 2016-04-27 Genzyme Corporation Combination therapy for treating breast cancer
RU2637088C2 (ru) 2010-09-01 2017-11-29 Джензим Корпорейшн Лечение инфаркта миокарда с использованием антагонистов tgf-бета

Also Published As

Publication number Publication date
TWI664979B (zh) 2019-07-11
EP3415633A1 (en) 2018-12-19
CY1121412T1 (el) 2020-05-29
ES2845215T3 (es) 2021-07-26
PT2971048T (pt) 2019-02-06
RU2015143156A (ru) 2017-04-13
US20170342144A1 (en) 2017-11-30
JP2016512521A (ja) 2016-04-28
EP3415633B1 (en) 2020-10-28
EP2971048A2 (en) 2016-01-20
AU2018203261B2 (en) 2020-03-26
US20160017026A1 (en) 2016-01-21
BR112015021595A2 (pt) 2017-10-10
CA2904847C (en) 2021-06-01
CN105229160A (zh) 2016-01-06
HUE042020T2 (hu) 2019-06-28
SI2971048T1 (sl) 2019-03-29
TWI613216B (zh) 2018-02-01
CN105229160B (zh) 2020-06-23
EP2971048B1 (en) 2018-10-31
TW201522369A (zh) 2015-06-16
HRP20190201T1 (hr) 2019-03-22
SG10201707021RA (en) 2017-10-30
AU2018203261A1 (en) 2018-05-31
JP6495884B2 (ja) 2019-04-03
HK1220731A1 (zh) 2017-05-12
KR102258457B1 (ko) 2021-05-31
DK2971048T3 (en) 2019-02-25
AR095240A1 (es) 2015-09-30
RU2681502C2 (ru) 2019-03-06
PL2971048T4 (pl) 2019-05-31
UY35384A (es) 2014-10-31
EP2971048A4 (en) 2016-11-02
WO2014164709A2 (en) 2014-10-09
AU2014249051A1 (en) 2015-10-01
WO2014164709A3 (en) 2014-12-24
MX365385B (es) 2019-05-31
IL241404A0 (en) 2015-11-30
SG11201507279XA (en) 2015-10-29
CA2904847A1 (en) 2014-10-09
KR20150126397A (ko) 2015-11-11
ES2713505T3 (es) 2019-05-22
US9783604B2 (en) 2017-10-10
AU2014249051B2 (en) 2018-02-15
TR201901415T4 (tr) 2019-02-21
PL2971048T3 (pl) 2019-05-31
TW201803592A (zh) 2018-02-01
LT2971048T (lt) 2019-02-25
US10730936B2 (en) 2020-08-04
IL241404B (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MX365385B (es) Anticuerpos anti-tgf-beta modificados genéticamente y fragmentos de unión a antígeno.
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2020010382A (es) Anticuerpos biespecificos para pd1 y tim3.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EP3702372A3 (en) Anti-cd40 human antibodies
ZA201604660B (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2018009228A (es) Proteínas de unión a antigeno que se unen a pd-l1.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
SG10201900571YA (en) Anti-pd-1 antibodies
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
NZ629913A (en) Anti-ox40 antibodies and methods of using the same
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
PE20150002A1 (es) Anticuerpos anti-fcrn
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
EP3029069A4 (en) Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof
EP4079760A3 (en) Antibodies against clostridium difficile toxins and methods of using the same
MX2019011585A (es) Anticuerpos miltiespecificos estables.
EP3904387A4 (en) MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO HUMAN TRBV-9
NZ710422A (en) Protein combination-based fv library, and preparation method therefor
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
EP2970491A4 (en) MONOCLONAL ANTIBODIES AGAINST EGFR AND USES THEREOF
UA111372C2 (uk) ФРАГМЕНТ Fab' АНТИТІЛА ПРОТИ NGF ЛЮДИНИ

Legal Events

Date Code Title Description
FG Grant or registration